SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT03083769

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Functional Genetic Variants Affecting Tacrolimus Trough Levels and Side Effects in Chinese Renal Transplantation.

The purpose of this study is to determine whether functional genetic variants can affect tacrolimus dose corrected trough levels and associate with the side effects in Chinese renal transplant recipients.

NCT03083769 Transplantation


Primary Outcomes

Description: We will measure the number of participants with acute rejection during the day 1 to day 61 after transplantation. Kaplan-Meier analyses were performed for acute rejection in participants with different genotypes.

Measure: Number of Participants With Acute Rejection

Time: Day 1 to Day 61

Description: We will measure the number of participants with tacrolimus-related nephrotoxicities during the day 1 to day 61 after transplantation. Kaplan-Meier analyses were performed for tacrolimus-related nephrotoxicities in participants with different genotypes.

Measure: Number of Participants With Tacrolimus-related Nephrotoxicities

Time: Day1 to Day 61

Description: We will measure the number of participants with tacrolimus-related neurotoxicities during the day 1 to day 61 after transplantation. Kaplan-Meier analyses were performed for tacrolimus-related neurotoxicities in participants with different genotypes.

Measure: Number of Participants With Tacrolimus-related Neurotoxicities

Time: Day1 to Day 61

Time Perspective: Other

Cohort


There is one SNP

SNPs


1 A6986G

Full understanding of this mechanism is important for the personalized use of tacrolimus and reducing the risk of side effects.The CYP3A5*3 (A6986G) resulting in a splicing defect and the absence of protein activity, was identified as a functional variant (Kuehl P.2001). --- A6986G ---



HPO Nodes